Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase

Stock Track

03/26

Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.

The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.

Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1100707834"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100707834\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100707834?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100707834","market":"hk","top_or_hot":-1,"title":"Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase","media":"Stock Track","content":"<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-26 09:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉醫療-B","start_time":0,"source_url":"","article_id":"1100707834","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100707834","pubTimestamp":1774490141,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"个股赛道|沛嘉医疗盘中大涨5.28%，得益于强劲的2025财年业绩、监管批准、CEO购股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}